Based on ratings from 0 stock analysts, the Kenvue Inc. Common Stock stock price is expected to increase by 6.62% in 12 months. This is calculated by using the average 12-month stock price forecast for Kenvue Inc. Common Stock. The lowest target is $21 and the highest is $27. Please note analyst price targets are not guaranteed and could be missed completely.
Kenvue Inc. Common Stock has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Kenvue Inc. Common Stock will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of KVUE.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Anna Lizzul B of A Securities | Buy | $27 | Maintains | Oct 22, 2024 |
Andrea Teixeira JP Morgan | Overweight | $25 | Maintains | Oct 11, 2024 |
Nik Modi RBC Capital | Sector Perform | $24 | Downgrade | Sep 24, 2024 |
Keith Devas Jefferies | Buy | $27 | Initiates | Sep 24, 2024 |
Korinne Wolfmeyer Piper Sandler | Neutral | $21 | Maintains | Sep 23, 2024 |
Nik Modi RBC Capital | Outperform | $24 | Reiterates | Aug 7, 2024 |
Steve Powers Deutsche Bank | Buy | $24 | Maintains | Aug 7, 2024 |
Peter Grom UBS | Neutral | $22 | Maintains | Aug 7, 2024 |
Andrea Teixeira JP Morgan | Overweight | $24 | Maintains | Aug 7, 2024 |
Steve Powers Deutsche Bank | Buy | $23 | Maintains | Jul 25, 2024 |
Andrea Teixeira JP Morgan | Overweight | $22 | Maintains | Jul 22, 2024 |
Citigroup | Neutral | Maintains | Jul 11, 2024 | |
Filippo Falorni Citigroup | Neutral | $20 | Maintains | Jul 10, 2024 |
Filippo Falorni Citigroup | Neutral | $21 | Reinstates | May 28, 2024 |
Jeremy Fialko HSBC | Hold | $21 | Maintains | May 8, 2024 |
Callum Elliott Bernstein | Underperform | $18 | Initiates | Apr 11, 2024 |
Jon Andersen William Blair | Market Perform | Initiates | Apr 3, 2024 | |
Bonnie Herzog Goldman Sachs | Neutral | $20 | Maintains | Mar 4, 2024 |
Bonnie Herzog Goldman Sachs | Neutral | $20 | Downgrade | Mar 1, 2024 |
Nik Modi RBC Capital | Outperform | $24 | Reiterates | Feb 13, 2024 |
When did it IPO
2023
Staff Count
22,000
Country
United States
Sector/Industry
Consumer Defensive/Household & Personal Products
CEO
Mr. Thibaut Mongon
Market Cap
$42.85B
In 2023, KVUE generated $15.44B in revenue, which was a increase of 3.30% from the previous year. This can be seen as a signal that KVUE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Kenvue (KVUE) is set to report its quarterly performance for September 2024, with key metrics being analyzed beyond Wall Street's estimates.
Why It Matters - Analyzing Kenvue's key metrics offers insights into its financial health and growth potential, influencing investment decisions and stock valuation ahead of quarterly results.
Summary - The news questions whether minor adjustments can enhance a stock's appeal to investors. Further details on specific changes or stock performance are not provided.
Why It Matters - The mention of "tinkering" suggests potential changes that could enhance the stock's appeal, signaling possible growth or improved performance, affecting investment decisions.
Summary - Kenvue Inc. (NYSE: KVUE) announced that Neutrogenaยฎ will form multi-year partnerships with Dr. Dhaval Bhanusali and Dr. Muneeb Shah.
Why It Matters - Kenvue's partnership with influencers could enhance brand visibility and drive sales for Neutrogena, positively impacting revenue and stock performance.
Summary - Starboard Value and Kenvue are reportedly aligned, suggesting favorable conditions for potential value creation.
Why It Matters - Alignment between Starboard Value and Kenvue signals potential strategic initiatives that could enhance profitability and shareholder value, attracting investor interest.
Summary - An activist investor has acquired a stake in Kenvue stock, indicating potential changes or initiatives to enhance shareholder value.
Why It Matters - An activist investor's stake in Kenvue can drive changes in management strategies, potentially enhancing shareholder value and influencing stock performance.
Summary - Citadel, led by Ken Griffin, has acquired 18 million shares of a lesser-known consumer health stock.
Why It Matters - Ken Griffin's Citadel acquiring 18 million shares signals strong confidence in the consumer health stock, potentially influencing other investors and driving price momentum.